How tear glands move proteins that affect eye health
Microtubule-based Transport in Lacrimal Gland Function
This project looks at how tiny transport systems in tear gland cells drive release of inflammatory proteins in people with Sjögren’s-related dry eye.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11128788 on NIH RePORTER |
What this research studies
Researchers study lacrimal (tear) gland cells in mouse models and lab samples to understand why the glands make and release elevated levels of the enzyme cathepsin S (CTSS) that can worsen eye inflammation. They focus on cellular transport along microtubules and on a signaling switch (PP2A) that may control CTSS production and secretion. The team tests whether changing these transport or signaling steps can reduce harmful proteins in tears without the side effects seen with direct CTSS blockers. Findings aim to point to new targets for therapies that restore healthier tear composition.
Who could benefit from this research
Good fit: People with Sjögren’s syndrome or severe dry eye tied to lacrimal gland inflammation would be the most relevant candidates for participation or future trials.
Not a fit: Patients whose dry eye is caused mainly by eyelid problems, environmental factors, or non–Sjögren’s mechanisms are less likely to benefit from findings focused on autoimmune lacrimal gland dysfunction.
Why it matters
Potential benefit: If successful, this work could reveal new ways to stop tear glands from releasing inflammatory proteins and lead to better treatments for Sjögren’s-associated dry eye.
How similar studies have performed: Previous animal studies showed CTSS blockade reduced eye symptoms and elevated CTSS is seen in patients, but human trials of CTSS inhibitors had complications, so this project pursues alternative cellular mechanisms.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Hamm-Alvarez, Sarah F — University of Southern California
- Study coordinator: Hamm-Alvarez, Sarah F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.